Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 1
2020 8
2021 3
2022 6
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
Kauer J, Freundt EP, Schmitt A, Weinhold N, Mai EK, Müller-Tidow C, Goldschmidt H, Raab MS, Kriegsmann K, Sauer S. Kauer J, et al. BMC Cancer. 2023 Nov 21;23(1):1132. doi: 10.1186/s12885-023-11507-9. BMC Cancer. 2023. PMID: 37990162 Free PMC article. Clinical Trial.
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.
Sauer S, Kriegsmann K, Nientiedt C, Schmitt A, Müller-Tidow C, Raab MS, Kauer J. Sauer S, et al. Among authors: kauer j. Transfus Med Hemother. 2023 Mar 24;50(5):371-381. doi: 10.1159/000529691. eCollection 2023 Oct. Transfus Med Hemother. 2023. PMID: 37936633 Free PMC article.
CD105 (Endoglin) as negative prognostic factor in AML.
Kauer J, Schwartz K, Tandler C, Hinterleitner C, Roerden M, Jung G, Salih HR, Heitmann JS, Märklin M. Kauer J, et al. Sci Rep. 2019 Dec 4;9(1):18337. doi: 10.1038/s41598-019-54767-x. Sci Rep. 2019. PMID: 31797971 Free PMC article.
Identification of CD105 (endoglin) as novel risk marker in CLL.
Greiner SM, Märklin M, Holzmayer S, Kaban K, Meyer S, Hinterleitner C, Tandler C, Hagelstein I, Jung G, Salih HR, Heitmann JS, Kauer J. Greiner SM, et al. Among authors: kauer j. Ann Hematol. 2022 Apr;101(4):773-780. doi: 10.1007/s00277-022-04756-4. Epub 2022 Jan 19. Ann Hematol. 2022. PMID: 35044512 Free PMC article.
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.
Mehta NK, Pfluegler M, Meetze K, Li B, Sindel I, Vogt F, Marklin M, Heitmann JS, Kauer J, Osburg L, Zekri L, Bühring HJ, Mueller S, Hörner S, Baeuerle PA, Michaelson JS, Jung G, Salih HR. Mehta NK, et al. Among authors: kauer j. J Immunother Cancer. 2022 Mar;10(3):e003882. doi: 10.1136/jitc-2021-003882. J Immunother Cancer. 2022. PMID: 35288466 Free PMC article.
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer.
Zekri L, Vogt F, Osburg L, Müller S, Kauer J, Manz T, Pflügler M, Maurer A, Heitmann JS, Hagelstein I, Märklin M, Hörner S, Todenhöfer T, Calaminus C, Stenzl A, Pichler B, la Fougère C, Schneider MA, Rammensee HG, Zender L, Sipos B, Salih HR, Jung G. Zekri L, et al. Among authors: kauer j. EMBO Mol Med. 2021 Feb 5;13(2):e11902. doi: 10.15252/emmm.201911902. Epub 2020 Dec 29. EMBO Mol Med. 2021. PMID: 33372710 Free PMC article.
23 results